-
Disability advocates let their voices be heard at symposium
A couple weeks ago, I co-emceed the Zero Project Asia Pacific Symposium 2025 with my
-
Building Protection: Vaccines and Dystrophinopathy
The PPMD team was recently joined by three clinical experts, Dr. Anne Pham-Huy (Pediatric Infectious
-
In Case You Missed It…
Quest Media is an innovative adaptive lifestyle platform from MDA. With the power of this
-
Exon-skipping therapy shows promise for DMD44
Delpacibart zotadirsen (del-zota), an investigational exon-skipping therapy from Avidity Biosciences, is demonstrating the potential to
-
Exon-skipping therapy shows promise for DMD44
Delpacibart zotadirsen (del-zota), an investigational exon-skipping therapy from Avidity Biosciences, is demonstrating the potential to
-
The how and why of living with limb-girdle muscular dystrophy
“He who has a why to live can bear almost any how.” — Friedrich Nietzsche I
-
Employer Matching Programs Double the Impact
Anybody who has made a monetary donation to support MDA’s mission knows well that their
-
Agamree : un premier traitement approuvé au Canada pour la DMD
Le 25 septembre 2025, Santé Canada a franchi une étape historique en approuvant AGAMREE® (vamorolone)
-
Just another Monday: Watch movie, do laundry, throw out my back
Mondays are one of my favorite days of the week as a busy mom to
-
CureDuchenne Cares Webinar: Optimizing Cardiac Outcomes in Duchenne
CureDuchenne and Andreas S. Barth, MD, PhD, FAHA, for a community webinar about Optimizing Cardiac
